home

J&J drops NGF blocker fulranumab

EVENTSpmlive2016-04-05 12:46 Read   140

Johnson & Johnson has returned the rights to fulranumab to Amgen, raising another question mark over the role of nerve growth factor (NGF) blockers as pain therapies.

GSK gene therapy tops CHMP recommendations

TrendPMLIVE2016-04-05 11:18 Read   152

The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of what could become the first corrective ex vivo gene therapy for children anywhere in the world.

Health Tip: Why Is My Skin Dry?

Healthdrugs2016-04-05 10:58 Read   95

Dry, itchy skin can be caused by a number of factors, from health conditions to age.

With Biotechnology Companies Leading the Way, Six Venture-Backed IPOs Recorded in First Quarter

Commentsyahoo2016-04-05 09:13 Read   91

Six venture-backed initial public offerings (IPOs) raised $574.5 million in the first quarter of 2016, according to the Exit Poll Report by Thomson Reuters and the National Venture Capital Association (NVCA)

Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases

R&DBusinesswire2016-04-05 08:59 Read   622

Given the company’s long-standing commitment to and expertise in liver disease, we are confident that Gilead is the ideal partner to accelerate and maximize the potential of the ACC inhibitor program” Tweet this

FDA proposes limit for inorganic arsenic in infant rice cereal

RegulatorFDA2016-04-02 12:48 Read   80

The U.S. Food and Drug Administration is taking steps to reduce inorganic arsenic in infant rice cereal, a leading source of arsenic exposure in infants. Relative to body weight, rice intake for infants, primarily through infant rice cereal, is about three times greater than for adults.

Infographic: FDA has drastically cut down drug approval times

Commentsmedcitynews2016-04-02 12:37 Read   99

The Food and Drug Administration has halved its approval time for new drugs since 2009, as illustrated in a colorful new infographic from the California Life Sciences Association and Boston Consulting Group.

Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

R&DFirstword2016-04-01 11:19 Read   88

Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from the first paroxysmal nocturnal hemoglobinuria (PNH) patient treated with subcutaneously administered Coversin.

Will SCOTUS take up Sandoz' pivotal biosim case? New briefs call on court to weigh in

CommentsFierce pharma2016-04-01 11:00 Read   152

Biosimilars advocates are lining up behind Sandoz to persuade the U.S. Supreme Court to take up its case against Amgen ($AMGN). The closely watched legal tussle, over Sandoz's biosim copy Amgen's blockbuster Neupogen, could define the timeline for biosimilars' paths to market.

Pfizer And Allergan Receive Request For Additional Information From Federal Trade Commission Regarding Proposed Combination

RegulatorPfizer 2016-04-01 10:49 Read   135

The request was fully anticipated as part of the regulatory process; Pfizer and Allergan continue to expect the transaction to close in the second half of 2016

Opdivo edges closer to first haematological cancer indication

RegulatorPlive2016-04-01 10:38 Read   179

The EU drugs regulator has started its review of Bristol-Myers Squibb's PD-1 inhibitor Opdivo in Hodgkin's lymphoma, which could be the first haematological cancer indication for a checkpoint inhibitor drug.

Health Tip: Managing a Food Allergy at Work

HealthDRUGS2016-04-01 10:11 Read   124

 Office lunches are a good opportunity to socialize with co-workers. But you should take precautions if you have a food allergy.